NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma

The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets Overall design: NF1 mutant and NF1 wild type melanoma short term cultures H3K27ac modifications were compared by Cut and Run to identify gene promoter activities differences